Trial · NCT07596485
RP-008 in Combination With Daily Oral Varenicline for the Treatment of Trigeminal Neuralgia
NCT07596485, Phase 1, Phase 2, Recruiting, Kriya Therapeutics, Inc.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. RP-008 in Combination With Daily Oral Varenicline for the Treatment of Trigeminal Neuralgia. Trials, record NCT07596485. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07596485
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- RP-008 in Combination With Daily Oral Varenicline for the Treatment of Trigeminal Neuralgia
- NCT number
- NCT07596485
- Status
- Recruiting
- Phases
- Phase 1, Phase 2
- Enrollment
- 24 participants, estimated
- Lead sponsor
- Kriya Therapeutics, Inc.
- Conditions
- Trigeminal Neuralgia
- Interventions
- RP-008, Varenicline tartrate
- First posted
- 2026-05-19
- Last updated
- 2026-10-23
Source ClinicalTrials.gov
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence and severity of adverse events, abnormal clinical laboratory values, abnormal physical examinations, abnormal vital signs, abnormal electrocardiograms (ECGs), and suicidal ideation | 12 months | Safety of RP-008 with varenicline |
| Secondary | Number of responders, defined as participants with reduced TN pain score, attacks, and severity, to RP-008 with varenicline treatment | 3 and 12 months | Efficacy of RP-008 with varenicline |
| Secondary | Change in pain as assessed by the 11-point Numerical Pain Rating Scale (NRS), where 0 corresponds to "no pain" and 10 corresponds to "pain as bad as you can imagine" | 3 and 12 months | Efficacy of RP-008 with varenicline |
| Secondary | Change in pain as assessed by the Brief Pain Inventory (BPI) Pain Interference (PI) sub-scale, where 0 corresponds to pain having no interference with daily activities and 10 corresponds to pain interfering completely with daily activities | 3 and 12 months | Efficacy of RP-008 with varenicline |
| Secondary | Change from baseline in Pittsburgh Sleep Quality Index (PSQI), where scores range from 0-21 and higher score indicates worse sleep quality | 3 and 12 months | Efficacy of RP-008 with varenicline |
| Secondary | Change from baseline in Hospital Anxiety and Depression Scale (HADS), where sub-scale scores range from 0-21 and higher score indicates greater symptom severity | 3 and 12 months | Efficacy of RP-008 with varenicline |
| Secondary | Change from baseline in Work Productivity and Activity Impairment (WPAI): Neuropathic Pain v2.0, where scores are expressed as 0-100% and higher percentage indicates greater impairment | 3 and 12 months | Efficacy of RP-008 with varenicline |
| Secondary | Change from baseline in Penn Facial Pain Scale Revised (Penn-FPS-R), where scores range from 0-120 and higher score indicates greater pain-related disability | 3 and 12 months | Efficacy of RP-008 with varenicline |
| Secondary | Change from baseline in 5-level EuroQual-5D (EQ-5D-5L), where scores range from 0-100 and higher scores indicate better health status | 3 and 12 months | Efficacy of RP-008 with varenicline |
| Secondary | Change from baseline in Patient Global Assessment of TN (PGA-TN), where scores range from 1 to 5 and higher score indicates higher severity of symptoms and inability to carry out normal activities | 3 and 12 months | Efficacy of RP-008 with varenicline |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07596485
GET https://conductscience.org/api/trials/v1/NCT07596485/registered